OmiCure® helps healthcare professionals match their cancer patients with up-to-date evidence-based therapies and diet. Input for this analysis is clinical and tumor profiling sequencing data from patients. OmiCure® identifies drugs and nutriments that can be used to target individual mutations, as well as, reporting on transcriptomic alterations of known tumor oncogenes

OmiCure® tests are Research Use Only products which has been neither approved nor reviewed by the FDA.

OmiCure® reports provide a comprehensive analysis revealing the tumors dysregulated genes as well as the associated therapies and nutriments’ options, in a simple to use format containing actionable knowledge and insights.

OmiCure® goes beyond standard DNA analysis by including the differential analysis of RNA expression in tumors. OmiCure® benefits from multiple international collaborations with leading personalized medicine consortia, including some of the world’s most renowned clinical centers.

OmiCure® uses an explainable Artificial Intelligence (xAI) technology to identify the ability of existing drugs to fight your specific tumor.

OmiCure® has the potential to revolutionize the effectiveness of cancer therapy, enabling the choice of the right treatment for the right patient, improving outcomes, avoiding unnecessary side effects as well as decreasing treatment costs.

OmiCure® matches the tumor's genomic signature with a massive database gathering available data from scientific publication and clinical trials worldwide, compiling more than forty thousands of chemical–disease associations, from multiple sources, including public databases, or proprietary academic-industry consortia

OmiCure® uses RNA data.
This approach was tested and validated through the WINTHER clinical trial. The results of this trial were published in Nature Medicine in April 2019. For the first time in a clinical setting, the WINTHER trial applied transcriptomics (gene expression) to guide decision. Using transcriptional analysis that specifically compared tumor to matched normal tissue, the trial was able to bring personalized cancer treatments to a greater number of patients.

We collaborate with a large number of public and private hospitals and research centers through a number of national and international collaborative projects. These include
Centre Leon Berard (France), Eurofins. Cancer Genome Interpreter is included under license from IRB Barcelona, ICREA and UPF.